Fortifying a meal with oyster mushroom powder beneficially affects postprandial glucagon-like peptide-1, non-esterified free fatty acids and hunger sensation in adults with impaired glucose tolerance: a double-blind randomized controlled crossover trial.

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

Impaired glucose tolerance (IGT) is a pathophysiological condition characterized by insulin resistance with known metabolic consequences such as postprandial hyperglycemia and hypertriglyceridemia.

Blood was collected before and repeatedly within 4 h after the meal to determine AUC of glucose (primary outcome), insulin, triglycerides, non-esterified free fatty acids (NEFAs), glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and ghrelin.

Why It Was Studied

German Clinical Trial Register on 09/08/2018; trial-ID: DRKS00015244.

Who Took Part

The abstract describes 22 subjects taking part.

The age groups tagged for this paper are adults.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

Appetite sensations (hunger, satiety, fullness, and desire to eat) were assessed before and after meal consumption by visual analog scales.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Fatty Acids, Nonesterified, Glucagon-Like Peptide 1, Glucose Intolerance, Hunger and Insulin.

The authors tagged it with the keywords Appetite sensations, Gastrointestinal hormones, Impaired glucose tolerance, Oyster mushrooms, Postprandial glucose and lipid metabolism and β-Glucans.

What This Means in Plain Language

The paper is a randomized and crossover study of Glucagon in 22 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (European journal of nutrition), a journal based in Germany.

More context: the Glucagon compound page, all human trials.